In the DN model, FXR deficiency accelerates kidney injury, and FXR agonist administration attenuates injury by decreasing proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis and by regulating lipid metabolism, particularly by decreasing the expression of SREBPs72. Here, NR1H4 is linked to glomerulosclerosis.